The result today is a continuation of growth for a growth company. The statutory EBITDA is down for known reasons. If the court case goes Nuix way, $2.50 is well possible. This is a half year result. The full year is more transparent because of the nature of new business. Overall, oversold on the statutory EBITDA. There are just as many buyers as sellers. Glass half full.
- Forums
- ASX - By Stock
- NXL
- $2.50 Party
$2.50 Party, page-18
Featured News
Add NXL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.15 |
Change
-0.350(5.38%) |
Mkt cap ! $2.021B |
Open | High | Low | Value | Volume |
$6.37 | $6.37 | $6.11 | $17.10M | 2.755M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 19149 | $6.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.17 | 8632 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 858 | 6.130 |
3 | 5750 | 6.100 |
2 | 1966 | 6.080 |
1 | 823 | 6.050 |
1 | 1000 | 6.010 |
Price($) | Vol. | No. |
---|---|---|
6.250 | 20000 | 1 |
6.300 | 747 | 1 |
6.340 | 6000 | 2 |
6.350 | 2600 | 2 |
6.360 | 1000 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
NXL (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online